Sector News

Bristol-Myers Squibb names Peter J. Arduini to board of directors

March 4, 2016
Life sciences

Bristol-Myers Squibb Company today announced that its Board of Directors has elected Peter J. Arduini to the Board, effective April 1, 2016. Mr. Arduini will serve as a member of the Audit Committee of the Board of Directors, effective May 3, 2016.

Mr. Arduini, 51, is currently president and chief executive officer and director of Integra LifeSciences, a leading global medical technology company. He joined Integra LifeSciences in 2010 as president and chief operating officer and director, and was named CEO in 2012. Mr. Arduini brings more than 25 years of global experience in medical device technology and pharmaceutical businesses, and has led operations in China, Europe, Japan and the U.S. Before joining Integra, Mr. Arduini was corporate vice president and president of Medication Delivery, Baxter Healthcare, which he joined in 2005. At Baxter, he was responsible for a portfolio focused on the inpatient acute care hospital market. Prior to joining Baxter, Mr. Arduini was responsible for the functional imaging business at General Electric Healthcare, where he spent 15 years assuming increasing levels of responsibility. Mr. Arduini serves on the Board of Directors of ADVAMED, the Advanced Medical Technology Association, and MDIC, the Medical Device Innovation Consortium. Mr. Arduini received his bachelor’s degree in marketing from Susquehanna University and a master’s in management from Northwestern University’s Kellogg School of Management.

“Pete is a confident and engaging leader who has delivered tremendous results throughout his career,” said Lamberto Andreotti, chairman, Bristol-Myers Squibb. “His commercial, financial and operational experience, along with a deep understanding of healthcare, make him an ideal choice for our Board. I look forward to his contributions.”

“Pete brings significant healthcare experience, unwavering integrity and a focus on helping patients,” said Giovanni Caforio, M.D., chief executive officer, Bristol-Myers Squibb. “Bristol-Myers Squibb will benefit from his insights as a strategic leader, and I am excited to have him join our Board.”

Source: Bristol-Myers Squibb

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”